Both in Biotechnology
Neurocrine Biosciences vs Kymera Therapeutics
Over the past year NBIX returned +2.9% and KYMR returned +112.0%; their daily moves had a correlation of 0.22.
NBIX +2.9% KYMR +112.0%Growth of $1, one year, split-adjusted
| Metric | NBIX | KYMR |
|---|---|---|
| Price | $146.10 | $126.63 |
| Market cap | $14.85B | $10.81B |
| Today | −0.19% | +3.29% |
| 1 month | +3.8% | +15.0% |
| 6 months | +10.9% | +56.9% |
| Year to date | +3.0% | +62.7% |
| 1 year | +5.9% | +110.9% |
| Revenue growth (YoY) | +39.5% | −100.0% |
| Gross margin | 97.6% | — |
| Net margin | 15.1% | — |
| P/E (TTM) | 21.1× | — |
| Price / sales | 4.4× | 105.7× |
| Net cash | $389.8M | $969.2M |
| Dividend yield | — | — |
| Volatility (60d) | 26.3% | 38.9% |
| Short % of float | 6.6% | 13.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).